Effient Beats Plavix In A Cost Study, But Will The Results Pass Muster With Payers?
This article was originally published in The Pink Sheet Daily
Executive Summary
Medco response: Study may not have shown a cost advantage for Effient if Plavix non-responders had been excluded.